Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis
- Status
- UNKNOWN
- Phase
- PHASE2
Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
The Efficacy of Transarterial Chemoinfusion (TAI) Combine Lenvatinib in Advanced Hepatocellular Carcinoma (HCC)
- Status
- UNKNOWN
- Phase
- PHASE3
The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
- Status
- UNKNOWN
- Phase
- PHASE3
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
HAIC Plus Lenvatinib and Toripalimab for Advanced HCC
- Status
- COMPLETED
- Phase
- PHASE2
Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- N/A
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
- Status
- COMPLETED
- Phase
- PHASE3
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
- Status
- WITHDRAWN
- Phase
- PHASE2
TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC
- Status
- UNKNOWN
- Phase
- PHASE3
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
- Status
- RECRUITING
- Phase
- PHASE2
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)
- Status
- COMPLETED
- Phase
- PHASE3